SINTN– Stanford Institute for Neuro-Innovation & Translational Neurosciences

Gregory W. Albers

Back to Profile

Diagnostic Utility of MRI in Intracerebral Hemorrhage

Contact Information

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Primary Contact:

Stephanie Kemp (650) 723-4481

Secondary Contact:

Eyngorn (650) 498-7333
To view all clinical trials at Stanford, please see the Clinical Trials Directory.

Brief

The overall aim of this project is to prospectively determine whether MRI can improve the conventional neuroradiological evaluation (CT with or without cerebral angiography) of patients with a spontaneous ICH or IVH. The study design will also allow us to identify the added benefit of specific MR sequences and repeat MRI in the chronic stage, thereby allowing us to prospectively determine their value in a consecutive series of patients. This information should have a major impact on the management of these patients by providing data on the diagnostic yield of routine MRI in patients presenting with a wide variety of causes for ICH or IVH. These data will help guide the diagnostic evaluation and the management of brain hemorrhage patients in the future.

Recruiting Status:

Recruiting

Stanford Recruiting Status:

Recruiting

Condition(s):

Intervention(s):

Phase:

N/A

Eligibility

Ages Eligible for Study:

18 years to Any Age

Genders Eligible for Study:

Male and Female

Health of Volunteers:

People with the conditions listed in this trial can not participate as controls.

Key Inclusion Criteria:

A. Men and non-pregnant women, at least 18 years of age.

B. Patients with an ICH or IVH admitted to Stanford University Medical center within 48 hours of symptom onset.

C. Ability to undergo MRI.

Key Exclusion Criteria:

A. Patients with a known (preexisting) source for ICH, for example a known untreated arterio-venous malformation.

B. Patients receiving investigational drug therapies or procedures prior to MRI scanning.

C. Glasgow coma scale (GCS) score < 6 in the absence of sedating medications.

D. Informed consent cannot be obtained either directly from the patient or from a legally authorized representative.

E. Severe coexisting or terminal systemic disease that limits life expectancy or that may interfere with the conduct of the study

Additional Study Details

Official Title:

Diagnostic Utility of MRI in Intracerebral Hemorrhage

Anticipated start date:

6/1/2006

Lead Sponsor:

Stanford University

Investigator(s):

Study Type:

Observational

Purpose:

NOTNEEDED

Duration:

Longitudinal

Selection:

Defined Population

Timing:

Prospective

Total Number to be Enrolled:

160

Total Number to be Enrolled at Stanford:

160

More Information

Trial Unique Id: 2 R01 NS034866-08A1

Locations & Contacts

Stanford Locations & Contacts:

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Primary Contact:

Stephanie Kemp (650) 723-4481

Secondary Contact:

Eyngorn (650) 498-7333

Non-Stanford Locations:

The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.

This listing was last updated:

9/11/2009

PLEASE NOTE:

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.

Stanford Medicine Resources:

Footer Links: